Evaluation of antitumor activity of a TGF-beta receptor i inhibitor (SD-208) on human colon adenocarcinoma

DARU, Journal of Pharmaceutical Sciences

Volumn 22, Issue 1, 2014, Pages

  Akbari, Abolfazl ^a   Amanpour, Saeid ^b   Muhammadnejad, Samad ^b   Ghahremani, Mohammad Hossein ^a,c   Ghaffari, Seyed Hamidollah ^d   Dehpour, Ahmad Reza ^e   Mobini, Gholam Reza ^a   Shidfar, Fatemeh ^a   Abastabar, Mahdi ^f   Khoshzaban, Ahad ^g   Faghihloo, Ebrahim ^a   Karimi, Abbas ^h   Heidari, Mansour ^e,g  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Immunohistochemistry staining; SD 208; SW 48

Indexed keywords

2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; ANTINEOPLASTIC AGENT; CD34 ANTIBODY; CD34 ANTIGEN; HEMATOXYLIN; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL MEMBRANE; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOPLASM; DRUG SCREENING; ENDOTHELIUM CELL; EVALUATION STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MITOSIS INDEX; MOUSE; NONHUMAN; TUMOR GROWTH;

EID: 84903818219     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-22-47     Document Type: Article

References (23)

1. Cancer statistics. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. The Genetic Basis of Human Cancer. Kinzler KW, Vogelstein B, New York: McGraw-Hill 2 2002 583 612
3. Signaling by chimeric erythropoietin-TGF-β receptors: homodimerization of the cytoplasmic domain of the type I TGF-β receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. Luo K, Lodish HF, EMBO J 1996 15 4485 4496 8887540 (Pubitemid 26294567)
4. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Siegel PM, Massague J, Nature Rev Cancer 2003 3 807 821 10.1038/nrc1208
5. Non-Smad TGF-β signals. Moustakas A, Heldin CH, J Cell Sci 2005 118 3573 3584 10.1242/jcs.02554 16105881 (Pubitemid 41309405)
6. High-throughput mapping of a dynamic signaling network in mammalian cells. Miriam Barrios R, Kevin R, Barish O, Rohit B, Zhong L, RS D, Fukiko SH, Yongmei L, Joanna D, Taylor IW, Valbona L, Mark R, Harukazu S, Yoshihide H, Igor J, Jeffrey LW, Science 2005 307 1621 1625 10.1126/science.1105776 15761153 (Pubitemid 40354744)
7. TGF-β and cancer. Bierie B, Moses HL, Cytokine Growth Factor Rev 2006 17 29 40 10.1016/j.cytogfr.2005.09.006 16289860 (Pubitemid 43117514)
8. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Levy L, Hill CS, Cytokine Growth Factor Rev 2006 17 41 58 10.1016/j.cytogfr.2005.09.009 16310402 (Pubitemid 43117515)
9. Development of TGF-β signaling inhibitors for cancer therapy. Yingling JM, Blanchard KL, Sawyer JS, Nature Rev Drug Discov 2004 3 1011 1022 10.1038/nrd1580 (Pubitemid 39642364)
10. The dual role of TGF in human cancer: from tumor suppression to cancer metastasis. Jean-Jacques L, ISRN Molecular Biology 2012 7 1 28
11. Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM, Biochemistry 2005 44 2293 2304 10.1021/bi048851x 15709742 (Pubitemid 40279534)
12. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Hill R, Song Y, Cardiff RD, Van Dyke T, Cell 2005 123 1001 1011 10.1016/j.cell.2005.09.030 16360031 (Pubitemid 41785416)
13. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS, Mol Pharmacol 2002 62 65 74 10.1124/mol.62.1.65 12065756 (Pubitemid 34680517)
14. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J, Cancer Res 2003 63 7791 7798 14633705
15. Requirement of TGF Signaling for SMO-mediated Carcinogenesis. Qipeng F, Miao H, Tao S, Xiaoli Z, Mala S, Bruce L, Xingbo Z, Jing Wu X, J Biol Chem 2010 47 36570 36576
16. TGFβ: the molecular Jekyll and Hyde of cancer. Bierie B, Harold LM, Nat Rev Cancer 2006 6 506 520 10.1038/nrc1926 16794634 (Pubitemid 43980540)
17. SD-208, a novel transforming growth factor-β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Uhl M, Steffen A, Jörg W, Markus W, Jing Ying M, Ramona A, Ruban M, Yu-Wang L, Michael P, Ulrich H, Alison M, Darren H, Wolfgang W, Higgins LS, Michael W, Cancer Res 2004 64 7954 7961 10.1158/0008-5472.CAN-04-1013 15520202 (Pubitemid 39446929)
18. Targeting endogenous transforming growth factor-β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Subramanian G, Schwarz RE, Linda H, Glenn M, Sarvajit C, Sundeep D, Michael R, Cancer Res 2004 64 5200 5211 10.1158/0008-5472.CAN-04-0018 15289325 (Pubitemid 39006539)
19. Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. Leung SY, Niimi A, Noble A, Oates T, Williams AS, Medicherla S, Protter AA, Chung KF, J Pharmacol Exp Ther 2006 319 586 594 10.1124/jpet.106. 109314 16888081
20. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M, Clin Cancer Res 2006 12 4315 4330 10.1158/1078-0432.CCR-06-0162 16857807
21. A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE, Cancer Res 2007 67 2351 2359 10.1158/0008-5472.CAN-06-2389 17332368 (Pubitemid 46424257)
22. TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Khalid SM, Delphine J, Pierrick GJ, Maria N, Ryan M, Xiang HP, Duong V, Lauren KD, Alain M, Theresa AG, Cancer Res 2011 71 175 184 10.1158/0008-5472.CAN-10-2651 21084275
23. Antitumor activity of TGF-β inhibitor is dependent on the microenvironment. Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS, Anticancer Res 2007 27 4149 4158 18229422